Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

VKTX is still an option on data quality, not a clean earnings compounder. The market is implicitly paying for a future obesity franchise, but the only read-through that can justify a durable rerate before the late-2027/2028 phase 3s is evidence that maintenance dosing preserves weight loss without creating a tolerability problem. If the switch from injectable to oral maintenance works, the equity is less about peak efficacy and more about reducing discontinuation risk, which is what ultimately drives payor adoption and duration of therapy.

The second-order competitive effect is more meaningful for LLY and NVO than the headline suggests: a credible oral-maintenance path would pressure the entire GLP-1 complex toward more patient-friendly regimens and could compress the premium attached to injectable-only products. But if the maintenance data are messy, VKTX likely trades like a financing-dependent biotech again, because the long-dated phase 3 timeline leaves a large valuation gap that can be re-priced quickly on tolerability concerns. In that scenario, the broad obesity basket is safer than single-name exposure.

The real catalyst is the current-quarter maintenance readout; everything else is mostly sentiment between now and 2027. The contrarian view is that the market may be overpaying for faster weight-loss velocity and underpricing discontinuation, which is the metric that matters for real-world share and reimbursement. Falsifiers are straightforward: no durable maintenance of weight loss after the switch, any AE/dropout inflection versus the injectable phase, or delays to the oral program start.